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Résumé 
Les données sur l'utilisation des médicaments sont généralement recueillies dans la 
recherche clinique. Pourtant, aucune méthode normalisée pour les catégoriser n’existe, que 
ce soit pour la description des échantillons ou pour l'étude de l'utilisation des médicaments 
comme une variable. Cette étude a été conçue pour développer un système de classification 
simple, sur une base empirique, pour la catégorisation d'utilisation des médicaments. Nous 
avons utilisé l'analyse factorielle pour réduire le nombre de groupements de médicaments 
possible. Cette analyse a fait émerger un modèle de constellations de consommation de 
médicaments qui semble caractériser des groupes cliniques spécifiques. Pour illustrer le 
potentiel de la technique, nous avons appliqué ce système de classification des échantillons 
où les troubles du sommeil sont importants: syndrome de fatigue chronique et l'apnée du 
sommeil. Notre méthode de classification a généré 5 facteurs qui semblent adhérer de façon 
logique. Ils ont été nommés: Médicaments cardiovasculaire/syndrome métabolique, 
Médicaments pour le soulagement des symptômes, Médicaments psychotropes, 
Médicaments préventifs et Médicaments hormonaux. Nos résultats démontrent que le profil 
des médicaments varie selon l'échantillon clinique. Le profil de médicament associé aux 
participants apnéiques reflète les conditions de comorbidité connues parmi ce groupe 
clinique, et le profil de médicament associé au Syndrome de fatigue chronique semble 
refléter la perception commune de cette condition comme étant un trouble psychogène. 
 
Mots-clés : classification des médicaments, le regroupement des médicaments, l'analyse 
factorielle, analyse en compSAHSntes principales, méthode
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Abstract 
Medication use data is usually collected in clinical research. Yet, no standardized method 
for categorizing these exists, either for sample description or for the study of medication 
use as a variable. The present investigation was designed to develop a simple, empirically 
based classification scheme for medication use categorization. We used factor analysis to 
reduce the number of possible medication groupings. This permitted a pattern of 
medication usage to emerge which appeared to characterize specific clinical constellations. 
To illustrate the technique’s potential, we applied this classification system to samples 
where sleep disorders are prominent: Chronic Fatigue Syndrome and Sleep Apnea. Our 
classification approach resulted in 5 factors that appear to cohere in a logical fashion. These 
were labeled: Cardiovascular / Metabolic Syndrome Medication, Symptom Relief 
Medication, Psychotropic Medication, Preventative Medication, and Hormonal Medication. 
Our findings show that medication profile varies according to clinical sample. The 
medication profile for participants with Sleep Apnea reflects known comorbid conditions; 
the medication profile associated with Chronic Fatigue Syndrome appears to reflect the 
common perception of this condition as a psychogenic disorder.   
 
Keywords : medication classification, medication grouping, factor analysis, principal 
components analysis, method 
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Introduction 
 
When clinical research involves recruitment from patient populations, we constantly have 
to reconcile the benefits of real-world relevance and ethical feasibility with the loss of 
experimental rigor. A very common “uncontrolled” variable is medication use. Most patients 
take at least one prescription medication and many take multiple prescription and over-the-
counter medications. However, these are seldom recorded in a systematic manner; they are not 
taken into account with respect to their potential effects and side effects, nor are they examined 
as possible health status indicators. The overall focus of this project was to develop a method for 
handling medication use data that is typically collected in clinical research but is rarely analyzed 
or reported on.   To illustrate the topic of medication in clinical research, the subject of sleep was 
selected as of general interest, and the present investigation focuses on the better understanding 
of medication profiles in individuals with sleep disorders. The present study addresses the 
following questions: Could a medication profile enhance the diagnostic process?  Might the 
medications for some constellations of symptoms help identify an underlying untreated sleep 
disorder? What other story might a classification system reveal in individuals with various 
clinical disorders?   
Although medication use data is usually collected in clinical research, no standardized 
method for categorizing these exists, either for sample description or use as a variable. In the 
present investigation we developed a simple, empirically based classification scheme to 
categorize medication. In order to illustrate the technique’s potential, we applied the 
classification system to samples where sleep disorders are prominent. This study selected two 
clinical disorders to demonstrate how this classification system can be used: sleep apnea, chronic 
fatigue syndrome.    
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Review of the literature 
Rationale for Medication Classification 
 
Generally, in clinical samples, participants consume a combination of medications in a 
single day. There is a clear need to systematize such data to enhance our understanding of patient 
samples and to clarify to associated risk factors. For example, the literature shows that 
cardiovascular, diabetic and lipid-lowering medications tend to be associated statistically, and 
this medication constellation characterizes people at elevated risk for developing aspects of 
cardiovascular / metabolic syndrome (Grundy et al., 2006; Donahue, 2008).  
Similarly, one would expect antidepressant, hypnotic and sedative use to be associated 
statistically, and in fact is characteristic of treatment for individuals with anxiety and depressive 
disorders, among other psychological/psychiatric diagnoses. Interestingly, this medication profile 
has also been associated with chronic fatigue syndrome (Creti, et al., 2010).   We believe that it 
is important to be able to quantify and describe medication use in a way that is both logical and 
meaningful, as well as to understand the interrelationships among medications and other aspects 
of patient health and functioning. Nowhere is this more critical than in the area of sleep 
disorders, particularly sleep apnea/hypopnea syndrome (SAHS), where patients who tend to be at 
greatest risk are older and/or have other medical conditions for which they are taking medication.  
The medication profile might also be informative in a poorly understood condition like CFS, 
where etiology and pathophysiology are unclear, but judging from their medication a 
psychological/psychiatric diagnostic bias is apparent (Libman et al., 2007). 
Previous studies 
 
Reeves et al. (2006) was one of the first groups to point out that medication data were 
lacking in most studies. Although these researchers took medications into account in their own 
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study, these were classified only as to their sedative or stimulant properties.  Of course, in any 
behavioral study one needs to know which sedatives or stimulants play a role in the findings.   
It has been suggested that it is potentially important to take participants’ medications into 
account in terms of their stimulant and sedative effects in psychobehavioral clinical studies 
related to our research area as well (Reeves, et al., 2006). In 2006, we also examined medications 
with respect to stimulating and sedating effects.  We implemented this suggestion in a previous 
study (Rizzo, et al., 2007a, 2007b) by demonstrating that a sample with SAHS could be 
distinguished from a sample that declined further investigation of their sleep (Decliners) on the 
basis of the sedative/stimulant properties of their medication profile.  Participants were two 
patient groups: (1) consecutive referrals to a sleep laboratory and (2) older adults in primary care. 
The relationship between stimulating and sedating medications and sleep/wake variables were 
explored for each group.  Results showed that the medication profiles differed according to 
group as well as to experienced sleep/wake difficulties (Rizzo, 2007b).   In that study: 1) 22% of 
the participants with SAHS used sedating medication versus 3% of those who did not have a 
diagnosis of apnea, 2) stimulating and neutral medication use were similar between groups, and 
3) severity of sleepiness and insomnia symptoms were significantly correlated with the number 
of sedative medications use by participants with apnea.  20% of the participants with SAHS used 
sedating medication vs 3% of Decliners.  Our conclusion of this study was that sedating 
medication use may reflect physicians’ attempts to address sleep problems in SAHS and may 
serve as an additional diagnostic signal for SAHS. 
The findings (a) contributed to our understanding of sleep disturbances and daytime 
complaints in patient samples, (b) underlined the importance of further investigating medication 
use in a more meticulous manner, and (c) raised the possibility of possible iatrogenic sleep 
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disorders, that is to say that sedatives may worsen the symptoms of untreated SAHS, for 
example.   
Effective management of medication  
The Emergence of E-files in Doctors’ Offices 
 
 The effective management of prescription medication has long been a struggle for 
physicians. In fact, to manage medication use, a group of McGill University researchers have 
developed software called Moxxi (Tamblyn, et al., 2005). Moxxi in an integrated electronic 
prescribing and drug management system for primary care in which some of the functionalities 
include: display of patient demographics, display of active drugs by pharmacy systems, and 
integration of electronic prescriptions into pharmacy software. To date, one pilot study was 
performed to assess the acceptability of the software by physicians: 61.5% (n=28) strongly 
agreed that they would use the MOXXI system for most their patients (Tamblyn, et al., 2005). 
This type of system could be of interest to studies of medication use.  
This tool was primarily designed to reduce errors related to prescribing (ex.: 
contraindications, interactions, etc.), however this type of system could be of interest to studies 
of medication use.   
For example, pharmacists would update their patients’ medication profiles in terms of 
active medications or discontinued medications; general practitioners are then able to access that 
information to have a better knowledge of prescriptions that have been filled.  Since medication 
information is entered electronically, the data is ready to use and accessible to health workers 
who obtain a permit.  Although this software is still being developed and trialed, our team of 
investigators inquired about data access by health researchers and what aspect of the software’s 
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use was considered throughout its conceptualization.  There appears to be “limited” profile 
access for researchers, in that names would be confidential and identified with a code.  
A team of researchers studied the impact of electronic prescribing on the 
professionalization of community pharmacists and showed that e-files improve the collaboration 
between pharmacists and physicians due to its easy to use technology (Motulsky, Winsdale, 
Tamblyn, Sicotte, 2008).  The potential of such a system to monitor medication profiles to 
enhance the diagnostic process has not yet been assessed. 
Medication classification scheme in two clinical entities 
  
To demonstrate how a medication classification system such as the one proposed in the 
present study might be applied, we have selected two clinical disorders: sleep apnea, a well 
defined primary sleep disorder with clear links to cardiovascular symptoms, and chronic fatigue 
syndrome, a poorly understood condition.  We will describe sleep apnea in relative detail, 
because there is more known about its recognized association with medical illness.  This 
constellation implies some interesting clinical and research possibilities for a medication profile 
derived by means of a user-friendly technique.   
Sleep Apnea and Health 
 
In the International Classification of Sleep Disorders (2001), obstructive sleep apnea 
(SAHS) is a dyssomnia of the intrinsic sleep disorders class “characterized by repetitive episodes 
of upper airway obstruction that occur during sleep, usually associated with a reduction in blood 
oxygen saturation”.   This breathing disorder, usually accompanied by very loud snoring and 
periodic lapses in breathing comes with a sensation of being unrefreshed in the morning due to 
the sleep disturbances.  Typically, people wake up momentarily when these stops in breathing 
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occur, and blood oxygenation decreases, sometimes as low as 50%.  They are often not aware of 
waking up in order to resume breathing.   
To diagnose SAHS, patients are sent to a sleep laboratory to perform an overnight 
polysomnography. Once other medical or sleep disorders have been ruled out, SAHS is 
diagnosed when at least 5 respiratory disturbances greater than 10 seconds occur an hour. 
Traditionally, the main symptom the individual experienced was believed to be severe daytime 
sleepiness.  Very recently, it has been demonstrated that daytime fatigue, as distinct from 
sleepiness, is an important symptom (Bailes, et al., 2008; 2010).  Sleep apnea is treated with a 
nasal continuous positive airway pressure (CPAP) working by keeping airway open under air 
pressure so that unobstructed breathing becomes possible.   
Consequences of this breathing disorder introduce a level of psycho-behavioural 
variability within the SAHS syndrome itself. One might appropriately assume that primary sleep 
disorders like SAHS, which restrict or disrupt sleep and cause some level of sleep loss, would 
result in substantial daytime sleepiness. Indeed, in clinical practice, case identification and 
referral for sleep disorder are typically centered on the evaluation of sleepiness, often employing 
the self-report Epworth Sleepiness Scale (Hardinge, Pitson, Stradling, 1995) to evaluate the 
severity of the condition.  It has been found recently that daytime fatigue is as frequent a 
symptom as sleepiness (Hossain et al., 2005; Bailes et al., 2010 ) and perhaps of even greater 
clinical significance (Bailes et al., in press, 2008; 2010).  Notably, there is a substantial number 
of individuals with sleep apnea who do not complain of the expected daytime sleepiness/fatigue 
symptoms (Young, et al., 1993).  In fact, patients with SAHS may present with a wide array of 
symptoms. Although some may report direct signs, such as loud snoring and sleep disruption, 
others report symptoms such as insomnia, headache, body pain, and depression, conditions 
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which often improve with the treatment of SAHS and reflect the disorder’s impact on other 
systems (Schwartz, Kohler, Karatinos, 2005; Sand, Hagen, Schrader, 2003).  This variability in 
presentation of SAHS-related complaints is likely an important factor in the under-recognition of 
SAHS by primary care physicians. 
Sleep apnea is under-recognized in primary care and, therefore, under-diagnosed and 
undertreated by sleep disorder specialists (Larsson, Lindberg, Franklin, & Lundback, 2003). 
Undiagnosed sleep apnea in Western countries is believed to be up to 5% of adults (Young, 
Peppard, Gottlieb, 2002).  Addressing the need for treatment for up to 5% of the population is a 
far-fetched vision, but facilitating the detection of sleep apnea may help increase its diagnosis.    
In recent years, there have been numerous studies highlighting the association of physical 
and psychological health aspects with sleep disorders. For example, in 1999, Spiegel, Leproult 
and Van Cauter examined the impact of sleep debt on health. They concluded that carbohydrate 
metabolism and endocrine function are both adversely affected by insufficient sleep. This 
adverse effect might be particularly salient in the context of age-related “metabolic syndrome”, 
which is characterized by of obesity, hypertension, hyperlipidemia, and/or diabetes. Recent 
epidemiological data showed that SAHS can be involved in the initiation or the progression of 
several cardiovascular diseases (ex.: Bradley & Floras, 2009). Furthermore, there is compelling 
experimental evidence that SAHS can raise blood pressure  which, in turn, increases 
cardiovascular risk; treatment of SAHS by continuous positive airway pressure (CPAP) can 
lower blood pressure. In addition, CPAP treatment has been found most effective in patients with 
increased blood pressure (Bradley & Floras, 2009). 
Difficulties in identifying SAHS 
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In the middle-aged work force, approximately 4% of men and 2% of women have SAHS 
(Coughlin et al., 2004), and only 20-60% of cases are believed to be identified in the older 
population (Ancoli-Israel S, et al., 1991; Ancoli-Israel & Coy, 1994; Ancoli-Israel, et al., 1996; 
Lichstein, Reidel, Lester, Aguillard, 1999).  There is a need for clear practice guidelines to 
identify patients who are likely to have sleep apnea as well as other sleep disorders (Reuveni, et 
al., 2004). In a previous study, we found a very high rate of sleep apnea (77% women, 98% men) 
in a self-selected sample.  These individuals volunteered upon reading a poster about a sleep 
study recruiting people who were feeling sleepy, fatigued or have insomnia, with no knowledge 
of the presence of a sleep disorder (Bailes et al., 2005).  Primary care physicians receive very 
little training in sleep disorders (Chung, Jairam, Hussain, & Shapiro, 2001), and even among 
sensitized practitioners, referral rates to sleep clinics for SAHS evaluation fall well short of the 
expected population rate (Kramer, Cook, Carlisle, Corwin, & Millman, 1999).  
In a previous study we demonstrated that a self-report measure which evaluates sleep 
disorder symptoms in older primary care patients can be used to derive a symptom constellation 
or “profile” that could identify patients who should be referred to a sleep clinic (Bailes et al., 
2007). This brief self-report measure, the Sleep Symptoms Checklist which produces symptom 
severity ratings in four domains, was designed as a practical diagnostic tool, useful in a busy 
general practice office. Adding patients' medical status as medication use information to this 
instrument may further enhance the physician's ability to direct at-risk patients to appropriate 
sleep laboratory screening, and this will be made easier with the emergence of e-files by looking 
at medication data that is already available.  
The potential usefulness of a research focus on medications has already been illustrated 
in such epidemiological studies as evaluation of the impact of prescription cost on population 
 
 
 9
health (Clark et al., 1995), the use of pharmaceutical data in the identification of patterns of 
chronic disease status (Von Korff, Wagner, Edward & Saunders, 1992), and prediction of one 
year mortality rates (Charlson, Pompei, Ales, & MacKenzie, 1987).  
Sleep apnea and Metabolic Syndrome Components  
 
Recent epidemiological studies demonstrated that SAHS contributes to the onset or 
progression of many cardiovascular diseases (Bradley & Floras, 2009), thus increasing the 
popularity of medical studies trying to understand sleep disorders.  For example, studies showed 
a greater prevalence of dyslipidemia among individuals with SAHS as compared with those 
without SAHS (Ip, et al., 2000; Schafer, et al., 2002; McArdle, Hillman, Beiling, Watts, 2007).   
As the concept of metabolic syndrome attracted increased attention in recent years, clear 
parameters were needed in order to establish this collection of disorders as a bona fide syndrome. 
One investigation demonstrated several parameters including medical treatment (ie. medication) 
for lipids and blood pressure as a parameter for diagnosing the metabolic syndrome 
(Handelsman, 2009). This suggests that researchers can use medication data as an indirect way to 
identify SAHS (ie.: as a proxy measure).  In fact, one study has already been carried out to 
investigate exposure to various prescription drugs as a proxy measure of disease (Grad, et al., 
1999). The Charleson Comorbidity Index was originally designed as a classification tool for 
comorbid conditions measuring the risk of 1-year mortality attributable to comorbidity in 
hospitalized patients (McGregor, et al., 2005, Charlson, et al., 1987).  The Index served as a 
validated tool for predicting mortality in longitudinal studies. In other words, the tool was 
developed for describing the effect of all other diseases an individual might have other than the 
primary disease of interest.  In the case of possible SAHS, if a person is taking medication for 
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hypertension in combination with the presence of a sleep complaint, then this may lead to the 
physician wanting to further investigate his-her patient’s sleep.   
In addition, in past studies, researchers were interested in determining if routine health 
care data from large automated databases could be used to generate inexpensive but valid 
measures of health status. An example is a study using the “Illness Scale” by Mossey and Roos 
(1987), who used insurance claims data to measure health status and the Chronic Disease Score 
(CDS) was used by Von Kroff et al. (1992) in an investigation where automated outpatient 
pharmacy data were used to measure chronic disease status among prescription drug users for 
overall health status.  
Chronic Fatigue syndrome (CFS) 
 
There are no diagnostic clinical signs or laboratory markers for CFS.  There is no specific 
pathophysiology, etiology, diagnostic tests or treatments linked to CFS (Libman et al., 2007).  
Concerns also arise about whether people with CFS are consuming medications to manage 
symptoms due to untreated CFS (ie. disability, pain). CFS is a syndrome with many uncertainties 
by both the patient and the caregiver. This syndrome can severely affect a person’s social life 
and functioning. The International Classification of Sleep Disorders’ only mention of CFS is the 
following: “Patients with the chronic fatigue syndrome (postinfectious neuromyasthenia) have 
similar findings to patients who report the onset of fibromyalgia following a febrile illness.”   
Complaints expressed by CFS sufferers are often misinterpreted as depression, laziness, 
somatoform or “in her/his head”.  Patient complaint is the only tool caregivers have to make a 
diagnosis.  Unfortunately, caregivers cannot make an easy diagnosis or detection of CFS and are 
left with a limited arbitrary diagnostic procedure when dealing with the syndrome.  Nevertheless, 
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having studied CFS participants in several of our studies, one characteristic was salient to us: 
their medication use.  Medication became a topic of interest since we also had collected this data 
in previous studies, but, except for sedative/stimulant effects, had not explored the implication 
further.  Currently, CFS diagnoses are done with an elimination process when no medical, 
psychiatric or drug can explain the presence of prolonged fatigue for at least 6 months along with 
a constellation of other symptoms (Boneva, 2009; Dinos et al., 2009).  Individuals with CFS are 
not routinely sent for evaluation of sleep disorders. It is widely recognized that there is a high 
percentage of undiagnosed sleep disorder in individuals with CFS in both study participants and 
clinical patients (Creti et al., 2010).  There is some controversy whether individuals with CFS 
symptoms and primary sleep disorder fit the diagnosis of CFS (Libman et al., 2009). 
Lombardi et al. (2009) report: “Chronic fatigue syndrome is a debilitating disease of 
unknown etiology that is estimated to affect 17 million people worldwide.” The prevalence of 
CFS is estimated between 400 and 2500 adults per 100 000 population. An analysis by the World 
Health Organization looked at 14 countries and showed that the prevalence of disabling fatigue 
to be 1.69% of the population and that significant costs are related to the inability to work and to 
the medical care needed (Dinos et al., 2009).  
In a recent study of sleep characteristics, individuals with CFS reported on their use of 
medications compared with healthy individuals (Boneva, et al., 2009).  Their study shows that 
participants with CFS are faced with a “polypharmacy” problem.  More specifically, more than 
90% of people with CFS used at least one drug or supplement with an average use of 5.8 drugs 
per person.  They compared individuals with CFS to “well” persons and persons with “CFS-like 
symptoms” and found that individuals with CFS use significantly more medication, especially 
antidepressants.   Interestingly, this group also raised the question of iatrogenic effects of 
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medication use as a key motive for looking at medication profiles in clinical practices.  Reeve’s 
team coded patient verbatim data, and then categorized them with the help of a physician review 
panel.  In the present study, we intend to classify medication information from physician reports 
into categories predetermined by the Canadian Compendium of Pharmaceuticals and Specialties 
(CPS) (electronic version, 2004) as the basis for the classification and coding procedure.   
Recent studies report  a viral basis for CFS (ie., XMRV, MLV) (eg.: Lombardi et al., 
2009; Vallings et al, 2009), but some data fail to support those findings (Erlwein et al, 2010)..   
The Present Study- Background 
 
Excluding individuals who take medication reduces ecological validity. Ignoring 
medication and its effects can confound the results. The number of different medications 
consumed by participants is often large and varied; available classificatory systems group 
medications based on a priori clinical criteria rather than on an empirical basis. Knowing what 
medications individuals take is vital because of their effects and side-effects on the variables of 
interest (e.g. Brownlee et al., 2003).  
The two clinical entities selected for the present study manifest nocturnal sleep disorder 
and both have daytime sleepiness and fatigue as prominent symptomatology. The aim was to 
demonstrate that individuals with common symptoms could be reliably distinguished from each 
clinical entity on the basis of medication profile alone. Clearly, rich details may be lost when 
there is no empirically sound way of grouping extensive lists of medications used by different 
clinical samples into a manageable number of categories.  
In the present study our goal was to develop a simple, empirically based classification 
system for the diverse medications that research participants may be using. The procedure 
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represents a standardized method to code drug use data to help with sample descriptions and to 
enable researchers to use medication as a variable in clinical research.  
Our study will compare individuals with SAHS, CFS and Healthy Controls to 
demonstrate that a specific medication profile may be developed for each clinical group. 
Our ongoing research required that we incorporate medication use into the analyses. This 
forced us to examine how medications could be combined into meaningful groupings to use in 
our project. Because this led us to a novel way of conceptualizing medication use in clinical 
research, in the present paper our goal is to share the results of our experience by demonstrating 
how researchers can develop a simple, empirically based classification system for the diverse 
medications that their research participants may be using. Thus, here we describe and illustrate a 
procedure that represents a standardized method to code drug use data in clinical research. The 
aim is to help with sample descriptions and to enable researchers to use medication as a variable 
in clinical research.  
What distinguishes this approach from the various existing systems is that it groups 
medications on an empirical basis, reflecting the attributes of the samples in question, rather than 
on the basis of clinical criteria, as do most conventional systems (e.g., the US National Drug 
Code Directory updated by the FDA/Center for Drug Evaluation and Research (UDHHS, 2008); 
the American Hospital Formulary Service Drug Information (AHFS DI) from the American 
Society of Health-System Pharmacists (ASHP); the WHO's Anatomical Therapeutic Chemical 
(ATC) Classification System). Thus, our technique both allows for the reduction of the number 
of medication groupings as well as permits the researchers to see the pattern of medication usage 
in specific clinical constellations. 
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In the present investigation, we used an existing data base for older individuals recruited 
from the community and from primary care, as well as a sample of individuals with CFS (Table 
1). The data base included uncoded, self-report information on what medications, prescription 
and over-the-counter, each participant was taking. We first developed a simple, empirically 
based classification scheme for medication use categorization. To illustrate the technique’s 
potential, we then applied this classification system to two samples where sleep disorders are 
prominent (SAHS, CFS) and on samples of control subjects.  We predicted that: 
 SAHS will be more associated with medication related to the metabolic syndrome 
 CFS will be more associated with psychotropic medications; 
 Healthy Controls will take fewer of the medication classes associated with clinical 
samples.   
The present study 
 
We plan to (a) develop a classification method to arrive at a medication profile, and (b) to 
demonstrate how such a profile could be used to (c) identify individuals with apnea and (d) 
distinguish these, on the basis of their medication profile, from another clinical disorder that 
shares many aspects of apnea symptomatology. 
 
Study 1: Development of the Classification System 
 
Method 
Participants: Phase 1 
To develop the classification system, we used 473 subjects from our database of 
participants who had been recruited for a series of sleep and fatigue related studies carried out in 
our laboratory. Overall sample characteristics are presented in Table 1.  
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Chronic fatigue syndrome (CFS) sample. (Libman, et al., 2007). Ninety-seven 
participants with CFS were part of a larger study of sleep disorders in this population (Fossey, et 
al., 2004; Creti, et al., 2004). These participants were diagnosed by a neurologist (see study 2 for 
specific criteria). 
Older primary care sample (Bailes, Baltzan, Alapin, Fichten, & Libman, 2005). Forty-
seven participants were older adults (ages 55 and over) recruited from primary care waiting 
rooms at three family practice centers in Montreal for a study of sleep disorders.  
Older community sample (Fichten, Libman, Creti, Bailes, & Sabourin, 2004). Two 
hundred and three participants were recruited from the community through media publicity 
consisting of press releases, presentations, and mailings to seniors' groups and notices in 
community clinics and residences for older adults. Individuals with daytime fatigue and/or 
sleepiness and/or insomnia were sought for a study of sleep disorders.  
Sleep clinic sample (Bailes, et al., 2008). Seventy-two participants were consecutive new 
patients referred for evaluation of possible sleep disorder at two hospital based sleep clinics in 
Montreal. They were recruited from sleep clinic waiting rooms. 
Healthy control sample (Bailes, et al., 2006). Fifty-four control group subjects were 
individuals with no diagnosed medical or psychiatric condition. They were recruited from the 
community through posters, announcements and personal contacts.  
Table 1
Sample Characteristics for the Medication Profile of Comparison Groups
Sample
n Males
Females
Mean age1    Males
Females
Control Group
22 24 77 46 15
Chronic Fatigue 
Syndrome (CFS)
Older        
Primary Care
Older 
Community Sleep Clinic
39
44.4(8.7) 70.9(10.4) 64.8(11.4) 54.0(11.4) 45.9(11.2)
75 23 126 26
45.3(10.3)46.5(11.2) 66.4(11.1) 65.7(10.7) 54.4(11.2)
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Procedure 
 
Data on medication use were collected as a routine part of our research protocol. These 
were grouped into the 43 specific therapeutic classes provided in the Canadian Compendium of 
Pharmaceuticals and Specialties (CPS) (electronic version, 2004). There are other systems 
derived for different purposes and used in different countries. Examples are the US National 
Drug Code Directory updated by the FDA/Center for Drug Evaluation and Research (UDHHS, 
2008), and the American Hospital Formulary Service Drug Information (AHFS DI) from the 
American Society of Health-System Pharmacists (ASHP). We used the Canadian Compendium 
of Pharmaceuticals and Specialties (CPS) (electronic version, 2004) as the basis for the 
classification and coding procedure for its convenience, availability, ease of use, and relevance to 
the Canadian health care system.  
Medications were classified into one of the 43 specific CPS therapeutic classes. Unused 
therapeutic classes (i.e., if no participants took any medication in this class) were excluded, 
leaving 27 therapeutic classes (see Table 2). Medication use was coded by indicating the number 
of different drugs used in each CPS therapeutic class for each participant. If the participant did 
not take a medication in a certain class, this was scored as “0”. A “1” was scored when a 
participant took one medication in a particular class. A score of “4” indicated that a participant 
took four different medications within the class. For example, if a participant took separate 
Vitamin A, C, D and calcium pills, they obtained a score of “4” in the “Vitamins” class.  
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Table 2
Number of Medications Taken in Each CPS Therapeutic Class Ranked by Popularity
CPS Therapeutic Classes
Maximum 
Number of 
Different 
Medications 
Taken by a 
Participant 
Within a Class
Total Number 
of Medications 
Taken in Each 
Class
Cardiovascular drugs 116 / 24.3% 5 199
Analgesics 71 / 14.9% 3 79
Lipid lowering agents 61 / 12.8% 2 63
Thyroid hormones 61 / 12.8% 1 61
Antidepressants 58 / 12.1% 2 64
Hypnotics and sedatives 40 / 8.4% 3 52
Gastrointestinal agents 36 / 7.5% 2 37
Sex hormones 34 / 7.1% 3 42
Vitamins and Minerals 33 / 6.9% 4 57
Anticonvulsants 30 / 6.3% 2 32
Diabetes therapy 28 / 5.9% 3 37
Diuretics 23 / 4.8% 1 23
Anticoagulants 18 / 3.8% 2 19
Corticosteroids, inhaled (incl. Asthma therapy) 16 / 3.4% 2 18
Osteoporosis therapy 16 / 3.4% 1 16
Prostatic hyperplasia therapy 15 / 3.1% 2 19
Respiratory system agents 12 / 2.5% 2 15
Antihistamines 11 / 2.3% 1 11
Antispasmodics 6 / 1.3% 1 6
Anemia therapy and Hematopoietics 3 / 0.6% 1 3
Antipsychotics 3 / 0.6% 1 3
Antiparkinsonian agents 2 / 0.4% 1 2
Corticosteroids, systemic 2 / 0.4% 2 3
Ophthalmologicals 2 / 0.4% 1 2
Immunosuppressive agents 1 / 0.2% 2 2
Mania therapy 1 / 0.2% 1 1
Rheumatic disease therapy 1 / 0.2% 1 1
Number of 
Participants 
Taking 
Medications 
Within a Class  
 
Results 
 
Data from all subjects were combined for this study and are presented in Table 2, which 
presents the number of medications taken in each CPS therapeutic class, including multiple 
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medications taken by individual participants.  To organize the data into more manageable classes 
for further analysis, we first reassigned medications taken 3 or fewer times into an “other” class, 
and then carried out a principal components factor analysis with varimax rotation on the 
remaining classes. This converged in 5 iterations and resulted in 5 factors. Examination of the 
scree plot, scree elbow curves, and eigenvalues (see Figure 1) indicated that a five factor solution 
was the most parsimonious.  Factor loadings of magnitude less than .4, with the eigenvalue 
greater than 1 criterion, were suppressed simply because we applied a general and rigorous 
cutoff rule for factor analysis. These can be seen in Table 3.  A guideline for identifying 
significant factor loadings based on sample size.  Significant (based on a .05 significance level) 
factor loadings based on sample size go as follows: n=350—.30;  n=250—.35;  n=200—.40;  
n=150—.45;  n=120—.50;  n=100—.55;  n=85—.60;  n=70—.65;  n=60—.70;  n=50—.75.( 
Hair, Babin, et al., 2003). 
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Figure 1 
 
Scree Test Graph For Medication Factor Loadings 
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Table 3
Medication Factor Loadings Based on CPS Therapeutic Class Frequencies
CPS Medication Classes
Factor 1:  
Cardiovascular/
Metabolic 
Disorder 
Medication
Factor 2: 
Symptom 
Relief 
Medication
Factor 3:  
Psychotropic 
Medication
Factor 4:  
Preventative 
Medication
Factor 5:  
Hormonal 
Medication
Cardiovascular drugs 0.75     
Lipid lowering agents 0.74    
Anticoagulants 0.66     
Diabetes therapy 0.64     
Diuretics 0.42     
Gastrointestinal agents 0.63
Respiratory system agents  0.58    
Corticosteroids, inhaled (incl. asthma therapy)  0.56    
Antihistamines  0.54    
Antispasmodics 0.47
Analgesics      
Anticonvulsants   0.74   
Hypnotics and sedatives   0.65   
Antidepressants   0.41   
Vitamins and Minerals    0.70  
Osteoporosis therapy    0.63  
Thyroid hormones     0.68
Sex hormones     0.60
Prostatic hyperplasia therapy  
 
Published guidelines for sample size in factor analysis include 2 options: 1) Absolute N 
and 2) N (number of participants) :p (observed variables) ratio.  In both cases, higher is better.  
When adopting the “absolute N” approach, the literature recommends several minimum sample 
sizes: N= 400 (Aleamoni 1976)  or a sample size evaluated with a suggested scale (50—very 
poor; 100—poor; 200—fair; 300—good; 500-very good; 1000 or more—excellent).Generally, 
larger samples minimize the probability of error as in other statistical analysis, but other rules 
about good statistical analyses may not apply to this method (e.g., increasing generalizability of 
the results).  The second approach -  N:p suggests a that increasing the ratio also increases the 
quality of the analysis.  A recommendation of a minimum ratio of 5:1-10:1 has been 
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recommended (Gorsuch 1983; Nunally 1978 respectively) In this study, we used a sample size of 
n=473 and a total of 20 variables, translating to a ratio of 23.7:1.   
We decided on principal component factor analysis with varimax rotation rather than 
cluster analysis for two key reasons: (a) cluster analysis, which can involve different techniques 
that yield very different results (Gorsuch, 1983), would also have made the data look more 
complex than factor analysis, and (b) it would not have permitted computing scores for each 
subject (Gorsuch, 1983; 1997), thereby limiting the utility of the method for clinical research.  
The 5 factors, labeled: Cardiovascular / Metabolic Syndrome Components Medication, 
Symptom Relief Medication, Psychotropic Medication, Preventative Medication, and Hormonal 
Medication, appear to cohere in a logical fashion (see Table 3). For example, Osteoporosis 
therapy and Vitamins and minerals loaded on Factor 4; this indicates that when participants use a 
medication for bone loss, for example, they are likely to take calcium or glucSAHSmine as well. 
Thus, the findings suggest that this method resulted in a series of medication groupings that 
cluster in a meaningful, valid way.  
The 473 participants summed 867 individual medications that they were taking of which 
only 57 are supplements.  Overall (n=473), medication use averaged 1.83 per person and the 5 
most frequently used medication categories were Cardiovascular Drugs (24.3%), Analgesics 
(14.9%), Lipid Lowering Agents (12.8%), Thyroid Hormones (12.8% and Antidepressants 
(12.1%).   Table 2 provides a list of all the medication categories and ranked by their popularity.  
To further understand the relationship between our medication variables, we performed a linear 
regression model predicting medication use by study groups.  We found that the adjusted R2 of 
our model is 0.251 with the R2 = .407.  Therefore, the linear regression explains 40.7% of the 
variance in the data.  F=2.618 with 22 degrees of freedom suggests that the test is highly 
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significant, thus we can assume that there is a linear relationship between the variables in our 
model.   
 
Study 2: Validating the Classification System - An Illustrative Example 
 
Method 
 
To evaluate empirical validity, in Study 2 we examined how meaningful these groupings 
are in a different sample of subjects. 
Subjects 
Subjects were a subset of those participating in Study 1. We selected those 107 
individuals from our data set who, after the initial assessment, were sent for a polysomnographic 
evaluation at a sleep laboratory to determine their sleep disorder status. Participants’ diagnoses 
fell into three groups: Chronic Fatigue Syndrome (CFS) with no Sleep Apnea/Hypopnea 
Syndrome (SAHS, n=23) aged 42.2 ±10.3, Sleep Apnea/Hypopnea Syndrome (SAHS) with no 
CFS (n=50) aged 59.7 ±11.6 , and a healthy comparison sample (Controls, n=34) aged 51.3 ±8.6. 
 The selection criteria for each group are as follow:  
- CFS sample (n=23): The CFS sample was recruited from physician referrals and 
CFS support groups. For each participant, two independent assessments of CFS 
were made. Participants arrived with a diagnosis from their own physician. The 
research team physician (neurologist) confirmed the original CFS diagnosis by 
using a standardized diagnostic instrument based on Fukuda et al.’s (1994) 
diagnostic criteria. None had ever been referred to a sleep laboratory and none 
had been diagnosed with a primary sleep disorder such as sleep apnea/hypopnea 
(Creti et al., 2004). 
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- SAHS sample (n=50): Participants underwent a 30-min assessment by the team 
respirologist (to evaluate medical reasons for nighttime and daytime complaints); 
and one night of PSG in a sleep laboratory to evaluate breathing and/or movement 
disorders. A nocturnal PSG assessment was carried out in a supervised sleep 
laboratory from 10 p.m. to 7 a.m. Monitoring included three leads EEG, EOG, 
bilateral anterior tibialis, and chin EMG, ECG, pulse oximetry, nasal and oral 
airflow with thermistor and nasal pressure cannulae, and respitrace bands for the 
measurement of respiratory effort. All signals were acquired on a digital data 
management system (Sandman, Nellcor-Puritan Bennett & Tyco, Ottawa, 
Canada). An apnea event was scored when there was a cessation of breathing for 
10 or more seconds. The cut-off criterion for defining a case with significant 
SAHS was 10 or more events per hour of EEG sleep (Bailes et al., 2005). 
- Healthy Comparison sample (n=34): Participants undergo polysomnographies 
resulting in no diagnosis for sleep disorders. 
 The ratio of male to female participants was 2.3:1 for individuals with SAHS, .05:1 for 
individuals with CFS and .31:1 for Healthy Controls, χ2 = 34.42, p = .000, indicating sex 
differences among the samples. Similarly, the comparison on age was significant, F(2,104) = 
25.21, p < 001. In spite of these findings, we decided not to covary sex or age because this 
example is presented for illustrative purposes only. A series of 1-way analysis of variance 
comparisons (ANOVA) was performed to compare the scores of the three groups on the five 
medication factors.  
 
Results 
 
 
 
 24
For our clinic samples (CFS and SAHS, n=73), their medications summed up to 210 
individual medications.  In other words, use of medications by clinical samples averaged 2.88 
per person.  More specifically, 78.3% of the CFS sample (n=23) takes at least one medication 
with an average of 1.91 medications per person (range 0-8), where Hypnotics ranked the highest 
in popularity.  86% of the SAHS sample (n=50) takes at least one medication with an average of 
3.32 medications per person (range 0-9), where Cardiovascular medication ranked highest in 
popularity (accounting for 30.7% of the total medication used by individuals with SAHS). As for 
Controls (n=34), they used a total of 20 individual medications, translated to an average use of 
.59 medications per person (range 0-2). The most popular medication category used by Controls 
was Thyroid Hormones.   
The factor analysis we then ran gave us groupings of medication categories (factors) that 
permitted is to statistically analyze the data of all 27 medication categories (listed in Table 2) that 
were being used by the overall sample.  
Table 4 shows significant differences among the three samples on medication factors: 
ANOVA and post-hoc results show that, as expected, individuals with CFS had significantly 
higher scores on the Psychotropic medication factor and individuals with SAHS had significantly 
higher scores on the Cardiovascular/metabolic syndrome components medication factor than the 
other two groups. In addition, individuals with SAHS had higher scores than the Control group 
on Preventative as well as on the Symptom relief medication factors. 
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Table 4
Factor Mean Scores and Test Results for the CFS, SAHS, and Control Groups
Medication Factors Group Mean SD n df F Sig. p = Post-Hoc
Cardiovascular/Metabolic Disorder Medication
SAHS 1.20 1.25 50 2 23.23 0.000 SAHS>CFS,C
 CFS 0.00 0.00 23
 Control 0.09 0.29 34
Symptom Relief Medication
 SAHS 0.54 0.61 50 2 3.33 0.040 SAHS>C
 CFS 0.52 1.16 23
 Control 0.15 0.44 34
Psychotropic Medication
 SAHS 0.38 0.75 50 2 9.67 0.000 CFS>SAHS,C
 CFS 0.87 0.81 23
 Control 0.09 0.29 34
Preventative Medication
SAHS 0.18 0.44 50 2 3.67 0.029 SAHS>C
 CFS 0.04 0.21 23
 Control 0.00 0.00 34
Hormonal Medication
SAHS 0.10 0.30 50 2 1.30 0.276
 CFS 0.13 0.34 23
 Control 0.24 0.50 34
 
 
Discussion 
 
Our study outlines a procedure for dealing with medication data which is routinely 
collected in many clinical research studies and which largely go unreported. We found that 
coding a wide array of medications based on a well-known classification system (in this case, the 
Canadian CPS) into therapeutic classes was a useful first approach to bring order to the chaos.  In 
this study we demonstrate this 3-step method: 
(1) identify which therapeutic class each medication belongs to,  
(2) discard low frequency therapeutic classes, and  
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(3) carry out principal components factor analysis. 
Deriving factors permitted us to study medication use as a variable in clinical research. 
Group comparisons yielded differences using the medication factors which would not have been 
discernable had we attempted to look at medications on a drug-by-drug basis. For example, we 
found that participants diagnosed with Sleep Apnea/Hypopnea Syndrome (SAHS) took 
significantly more medications in the Cardiovascular/metabolic syndrome category than did 
either those with CFS or healthy controls. The literature shows that untreated SAHS is strongly 
associated with cardiovascular medication (cf. Otake, Delaive, Walld, Manfreda, & Kryger, 
2008), and with hypertension, insulin resistance, and cardiovascular events, including stroke and 
arterial fibrillation (Hirshkowitz, 2008, Chowdhuri, Crook, Taylor, & Badr, 2008). Because our 
data reflect medication use prior to the sleep disorder diagnosis, we are now able to evaluate 
whether treatment of the SAHS might result in less medication and improved cardiovascular 
status. Of course such diagnostic and treatment implications need to be verified for other medical 
conditions.   
Our findings show that in a single day, our participants generally consumed a 
combination of medications. The use of factor analysis allowed us to reduce medications in the 
various CPS therapeutic classes into five coherent groupings. Notably, the system allows one to 
include multiple anxiolytics, antidepressives, and over the counter medications, for example, and 
to see the pattern of medication usage in any particular clinical constellation. It has already been 
shown that use of cardiovascular, diabetic and lipid-lowering medications tend to be associated 
statistically, and are characteristic of people at elevated risk for developing cardiovascular / 
metabolic disorders (Grundy et al., 2006; Donahue, 2008). It has been shown antidepressants, 
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hypnotics and sedatives are also associated statistically and are characteristic of treatment for 
individuals with Chronic Fatigue Syndrome (Creti, et al., 2010).  
What is of particular interest in the present study is that not only do the constellations of 
medications describe the two samples in a meaningful way, but in the case of SAHS, medication 
usage reflects known comorbid conditions, which might be useful to assist in the diagnosis of 
this condition. On the other hand, the medication profile characteristic of CFS appears to reflect 
the common perception of this condition as a psychogenic disorder. Furthermore, the profile 
does not have the same diagnostic usefulness as the SAHS profile; for CFS, the medications used 
might even exacerbate existing symptoms. 
A recent study of CPAP adherence reported that treating the sleep disorder was an 
effective way of managing both daytime sleepiness and hypertension (Gagnadoux et al., 2009).  
One might wonder if the reverse is the case as well; Are the medications for metabolic syndrome 
being consumed as an indirect way to treat the apnea?  How often are the consequences of an 
unrecognized condition (apnea) being treated rather than the disorder itself?   
The factors derived in the present study likely reflect medication use patterns only in 
clinical samples characterized by disrupted sleep or chronic fatigue. Most likely, other clinical 
samples will have very different medication profiles. It may well be that the same medications 
may group into different factors with other disorders. This may be considered a limitation of the 
present investigation, we believe that the benefits of this technique, which allows us to discover, 
in an empirical manner, the constellation of medications that group together in various clinical 
categories, outweighs the disadvantages. As is the case in our own samples, in other disorders, as 
well, the procedure may enhance the diagnostic process or, as in the case of CFS, reflect a 
possible distortion by the medical community in prematurely labeling the illness as psychogenic. 
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Thus, a prognostic model’s external validity can be determined for its planned use or purpose 
(Iezzioni, 1999).  
A definite limitation is that the technique itself is not fully descriptive. For example, 
medications that were popular in all samples, such as analgesics, did not load on any of the 
derived factors, and therefore did not differentiate groups. Therefore, such medications must be 
noted and handled separately in statistical procedures. Another limitation is that most of the 
frequencies in our samples were low and, thus, extreme scores may have had undue influence on 
the results.  
Therefore, our findings are illustrative of an easy way to implement a three-step method 
to derive empirically based medication classification categories for use in clinical research, 
rather than as a conclusive classificatory system. 
It is notable that the medication profiles derived in the present study were the result of a 
secondary analysis of data for the two samples. The next step is to include the medication 
classification system as part of the initial study design. Our team is embarking on a longitudinal 
project evaluating sleep apnea and metabolic syndrome, with the aim of determining which 
condition predicts the other. This will allow us to examine medication profiles for individuals 
diagnosed with SAHS or with metabolic syndrome aspects , to evaluate what differences exist 
between these two groups. The design also permits a re-evaluation of the profile two years after 
original diagnosis to add a longitudinal perspective. with enhanced diagnostic possibilities. 
Conclusions 
 
In conclusion, the findings of this study add to the meager literature on medication 
profiles and their relationship to clinical disorders. Our method of drug classification suggests 
that factor analysis: (a) affords an empirical means of deriving medication profiles for clinical 
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samples in health-related research and, (b) offers a useful and simple method for handling 
medication data in an intuitively appealing way, (c) adds a descriptive dimension that might 
enhance diagnostic process or reveal a distorted diagnostic bias. 
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